Skip to main content
. Author manuscript; available in PMC: 2006 Jan 25.
Published in final edited form as: Pharm Res. 2005 Nov 3;22(12):2107–2114. doi: 10.1007/s11095-005-8343-0

Figure 3.

Figure 3

Plasma concentrations versus time profiles of tritiated [3H] paclitaxel upon intravenous administration to SKOV-3 human ovarian adenocarcinoma-bearing nude mice. Paclitaxel was administered in aqueous solution as control (^), in poly(ethylene oxide)-modified poly(ɛ-caprolactone) nanoparticles (▪), and poly(ethylene oxide)-modified poly(β-amino ester) (PbAE) nanoparticles (▴).